Human VEGF R1/Flt-1 Quantikine ELISA Kit

Product is in the process of discontinuation and replaced by catalog # DVR100C.
(45 citations)   
  • Assay Length
    4.5 hours
  • Sample Type & Volume Required Per Well
    Cell Culture Supernates (100 uL), Serum (100 uL), EDTA Plasma (100 uL), Saliva (100 uL), Follicular Fluid (100 uL)
  • Sensitivity
    13.3 pg/mL
  • Assay Range
    31.2 - 2,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Saliva, Follicular Fluid)
  • Specificity
    Natural and recombinant human soluble VEGF R1
  • Cross-reactivity
    < 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
  • Interference
    No significant interference observed with available related molecules.
Control Available
QC239, Quantikine Immunoassay Control Set 935 for Human VEGF R1 - Please Inquire
Product Summary
The Quantikine Human VEGF R1 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human soluble VEGF R1 in cell culture supernates, serum, plasma, saliva, and follicular fluid. It contains Sf 21-expressed recombinant human VEGF R1/Fc Chimera and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human VEGF R1 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring soluble VEGF R1.

Precision
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision.
Cell Culture Supernates, Cell Lysates, Serum, EDTA Plasma, Heparin Plasma, Saliva
Intra-Assay Precision Inter-Assay Precision
Sample123123
n202020202020
Mean20761012072076161205
Standard Deviation5.1614.935.613.938.974
CV%2.52.42.96.76.36.1

Cell Culture Supernates, Serum, EDTA Plasma, Saliva, Follicular Fluid
Intra-Assay Precision Inter-Assay Precision
Sample123123
n202020202020
Mean96.659612131126451279
Standard Deviation2.522.839.31144.970.5
CV%2.63.83.29.875.5

Recovery

The recovery of VEGF R1 spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 100 86-113
EDTA Plasma (n=4) 99 89-105
Serum (n=4) 103 96-107
Linearity
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of VEGF R1 were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human VEGF R1/Flt-1 Quantikine ELISA Kit
Preparation and Storage
  • Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: VEGF R1/Flt-1

VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

    • Long Name
      Vascular Endothelial Growth Factor Receptor 1
    • Entrez Gene IDs
      2321 (Human); 14254 (Mouse);
    • Alternate Names
      EC 2.7.10; EC 2.7.10.1; FLT; FLT1; Flt-1; Fms-like tyrosine kinase 1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor); FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; vascular endothelial growth factor receptor 1; Vascular permeability factor receptor; VEGF R1; VEGFR1; VEGFR-1;
    Related Research Areas
    Citations:

    R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

    45 Citations: Showing 1 - 10
    Filter your results:

    Species
    Sample Type
    1. Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles
      Authors: M O'Brien, D Baczyk, JC Kingdom
      Sci Rep, 2017;7(1):5887.
      Species: Human
      Sample Type: Tissue Culture Supernates
    2. Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia
      PLoS ONE, 2016;11(9):e0162652.
      Species: Human
      Sample Type: Plasma
    3. Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia
      Authors: Ingrid C Weel
      PLoS ONE, 2016;11(6):e0157584.
      Species: Human
      Sample Type: Tissue Homogenates
    4. Inhibition of placental growth factor in renal cell carcinoma.
      Authors: Bessho H, Wong B, Huang D, Siew E, Huang D, Tan J, Ong C, Tan S, Matsumoto K, Iwamura M, Teh B
      Anticancer Res, 2015;35(1):531-41.
      Species: Human
      Sample Type: Cell Culture Supernates
    5. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
      Authors: Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz L, Morosi C, Crippa F, Fare E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud F, Salvioni R, Daidone M, Gianni A, Mariani L
      Br J Cancer, 2014;110(1):26-33.
      Species: Human
      Sample Type: Plasma
    6. FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.
      Authors: Owen, Leah A, Morrison, Margaux, Ahn, Jeeyun, Woo, Se Joon, Sato, Hajime, Robinson, Rosann, Morgan, Denise J, Zacharaki, Fani, Simeonova, Marina, Uehara, Hironori, Chakravarthy, Usha, Hogg, Ruth E, Ambati, Balamura, Kotoula, Maria, Baehr, Wolfgang, Haider, Neena B, Silvestri, Giuliana, Miller, Joan W, Tsironi, Evangeli, Farrer, Lindsay, Kim, Ivana K, Park, Kyu Hyun, DeAngelis, Margaret
      Invest Ophthalmol Vis Sci, 2014;55(6):3543-54.
      Species: Human
      Sample Type: Serum
    7. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury.
      Authors: White W, Garrett A, Craici I, Wagner S, Fitz-Gibbon P, Butters K, Brost B, Rose C, Grande J, Garovic V
      PLoS ONE, 2014;9(3):e92693.
      Species: Human
      Sample Type: Serum
    8. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
      Authors: Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla-Herttuala S, Anttila M
      BMC Cancer, 2014;14(0):696.
      Species: Human
      Sample Type: Serum
    9. Placental growth factor and soluble Fms-like tyrosine kinase 1 in diabetic pregnancy: A possible relation to distal villous immaturity.
      Authors: El-Tarhouny S, Almasry S, Elfayomy A, Baghdadi H, Habib F
      Histol Histopathol, 2014;29(2):259-72.
      Species: Human
      Sample Type: Serum
    10. Advanced oxidation protein products enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts: a possible link between oxidative stress and preeclampsia.
      Authors: Huang Q, Wang S, Zhang M, Huang L, Tian J, Yu Y, Wang Z, Zhong M
      Placenta, 2013;34(10):949-52.
      Species: Human
      Sample Type: Cell Culture Supernates
    11. Fcgamma receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.
      Authors: Justiniano S, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda J, Mo X, Cheney C, Hertlein E, Eubank T, Marsh C, Muthusamy N, Butchar J, Byrd J, Tridandapani S
      J Biol Chem, 2013;288(37):26800-9.
      Species: Human
      Sample Type: Cell Culture Supernates
    12. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
      Authors: Braicu E, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W, Sehouli J
      Cytokine, 2013;61(3):755-8.
      Species: Human
      Sample Type: Serum
    13. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment.
      Authors: Suzuki T, Shimada H, Makizako H, Doi T, Yoshida D, Ito K, Shimokata H, Washimi Y, Endo H, Kato T
      PLoS ONE, 2013;8(4):e61483.
      Species: Human
      Sample Type: Serum
    14. Integrating multiple 'omics' analyses identifies serological protein biomarkers for preeclampsia.
      Authors: Liu, Linda Y, Yang, Ting, Ji, Jun, Wen, Qiaojun, Morgan, Alexande, Jin, Bo, Chen, Gongxing, Lyell, Deirdre, Stevenson, David K, Ling, Xuefeng, Butte, Atul J
      BMC Med, 2013;11(0):236.
      Species: Human
      Sample Type: Serum
    15. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.
      Authors: Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z
      Nature, 2012;485(7398):333-8.
      Species: Human
      Sample Type: Plasma
    16. Prognostic significance of angiogenic factors in uterine cervical cancer.
      Authors: Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S
      Anticancer Res., 2011;31(8):2589-95.
      Species: Human
      Sample Type: Serum
    17. In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer.
      Authors: Landt S, Heidecke H, Korlach S, Reuter C, Schwidde I, Barinoff J, Thill M, Sehouli J, Kummel S
      Anticancer Res., 2011;31(8):2609-15.
      Species: Human
      Sample Type: Serum
    18. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer.
      Authors: Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Buchler MW, Weitz J, Koch M
      BMC Cancer, 2011;11(0):286.
      Species: Human
      Sample Type: Serum
    19. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
      Authors: Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM
      Clin. Cancer Res., 2011;17(15):5113-22.
      Species: Human
      Sample Type: Plasma
    20. Effect of smoking on circulating angiogenic factors in high risk pregnancies.
      Authors: Jeyabalan A, Powers RW, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M, Caritis S, Roberts JM, Kuller J, Cotroneo M, Kamon T, Mercer B, Ramsey R, Paul R, Rabello Y, McCart D, Mueller E, Goldenberg R, Copper R, Sorokin Y, Norman G, Millinder A, Christmas JT, McCoy S, Elder S, Elder N, Carter B, Pemberton V, Thurnau G, Meier A, Minton V, Meis P, Swain M, Moawad AH, Jones P, Iams JD, Meadows S, Brenner S, Collins B, Newman RB, Carter SG, Romero R, Sabo V, Thom E, Bain RP, MacPherson C, Johnson D, Fischer ML, McNellis D, Spong C, Catz C, Yaffe S
      PLoS ONE, 2010;5(10):e13270.
      Species: Human
      Sample Type: Serum
    21. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia.
      Authors: Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H
      Am. J. Obstet. Gynecol., 2010;202(2):161.e1-161.e1.
      Species: Human
      Sample Type: Serum
    22. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.
      Authors: Kosugi T, Nakayama T, Li Q, Chiodo VA, Zhang L, Campbell-Thompson M, Grant M, Croker BP, Nakagawa T
      Am. J. Physiol. Renal Physiol., 2010;298(3):F609-16.
      Species: Human
      Sample Type: Urine
    23. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
      Authors: Powers RW, Jeyabalan A, Clifton RG
      PLoS ONE, 2010;5(10):e13263.
      Species: Human
      Sample Type: Serum
    24. Periodic assessment of plasma sFlt-1 and PlGF concentrations and its association with placental morphometry in gestational hypertension (GH) - a prospective follow-up study.
      Authors: Jeevaratnam K, Nadarajah VD, Judson JP
      BMC Pregnancy Childbirth, 2010;10(0):58.
      Species: Human
      Sample Type: Plasma
    25. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis.
      Authors: Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M
      Fertil. Steril., 2010;94(1):52-7.
      Species: Human
      Sample Type: Serum
    26. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study.
      Authors: Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber B, Patsch JR, Schratzberger P
      Atherosclerosis, 2009;206(1):265-9.
      Species: Human
      Sample Type: Plasma
    27. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study.
      Authors: Levine RJ, Vatten LJ, Horowitz GL
      BMJ, 2009;339(0):b4336.
      Species: Human
      Sample Type: Serum
    28. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
      Authors: Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S
      Mol. Ther., 2009;17(2):278-84.
      Species: Human
      Sample Type: Plasma
    29. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia.
      Authors: Jeyabalan A, Powers RW, Durica AR, Harger GF, Roberts JM, Ness RB
      Am. J. Hypertens., 2008;21(8):943-7.
      Species: Human
      Sample Type: Plasma
    30. Natural selection of FLT1 alleles and their association with malaria resistance in utero.
      Authors: Muehlenbachs A, Fried M, Lachowitzer J, Mutabingwa TK, Duffy PE
      Proc. Natl. Acad. Sci. U.S.A., 2008;105(38):14488-91.
      Species: Human
      Sample Type: Cell Culture Supernates
    31. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis.
      Authors: Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E
      Fertil. Steril., 2008;89(4):922-6.
      Species: Human
      Sample Type: Serum
    32. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
      Authors: Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD
      J. Am. Coll. Cardiol., 2008;52(5):387-93.
      Species: Human
      Sample Type: Plasma
    33. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction.
      Authors: Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D
      Clin. Sci., 2007;112(1):51-7.
      Species: Human
      Sample Type: Serum
    34. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients.
      Authors: Caine GJ, Ryan P, Lip GY, Blann AD
      Cancer Lett., 2007;251(2):296-301.
      Species: Human
      Sample Type: Plasma
    35. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction.
      Authors: Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Menard JF, Pouplin S, Boumier P, Vittecoq O, Le Loet X, Boissier MC
      Clin. Immunol., 2007;124(2):158-64.
      Species: Human
      Sample Type: Serum
    36. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
      Authors: Caine GJ, Stonelake PS, Lip GY, Blann AD
      Cancer Lett., 2007;248(1):131-6.
      Species: Human
      Sample Type: Plasma
    37. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
      Authors: Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA
      N. Engl. J. Med., 2006;355(10):992-1005.
      Species: Human
      Sample Type: Serum
    38. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis.
      Authors: Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y
      Am. J. Obstet. Gynecol., 2006;194(2):551-6.
      Species: Human
      Sample Type: Serum
    39. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
      Authors: Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Gunther C, Laurent D, Unger C
      Eur. J. Cancer, 2005;41(9):1291-9.
      Species: Human
      Sample Type: Serum
    40. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta.
      Authors: Li H, Gu B, Zhang Y, Lewis DF, Wang Y
      Placenta, 2005;26(2):210-7.
      Species: Human
      Sample Type: Cell Culture Supernates
    41. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia.
      Authors: Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA
      Am. J. Obstet. Gynecol., 2005;192(3):734-41.
      Species: Human
      Sample Type: Urine
    42. Urinary placental growth factor and risk of preeclampsia.
      Authors: Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA
      JAMA, 2005;293(1):77-85.
      Species: Human
      Sample Type: Urine
    43. Circulating angiogenic factors and the risk of preeclampsia.
      Authors: Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA
      N. Engl. J. Med., 2004;350(7):672-83.
      Species: Human
      Sample Type: Serum
    44. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.
      Authors: Eubank TD, Roberts R, Galloway M, Wang Y, Cohn DE, Marsh CB
      Immunity, 2004;21(6):831-42.
      Species: Human
      Sample Type: Cell Culture Supernates
    45. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
      Authors: Maynard SE, Min JY, Merchan J, Lim KH, Mondal S, Stillman IE, Epstein FH, Karumanchi SA
      J. Clin. Invest., 2003;111(5):649-58.
      Species: Human
      Sample Type: Serum
    Expand to show all 45 Citations
    ELISA Controls
    Description Application Cat# Citations Images  

    Quantikine Immunoassay Control Set 935 for Human VEGF R1

    QC239
    View Sizes & Prices
    Catalog# Size Price Stock Quantity
    Loading Information....

    Have you used Human VEGF R1/Flt-1 Quantikine ELISA Kit?

    Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

    Order Details

    Contact Information

    R&D Systems Guarantee

    Associated Pathways

    Customers Who Viewed
    This Item Also Viewed

    Feedback

    Customer Information